OLIGOMETASTATIC PROSTATE CARCINOMA
Clinical trials for OLIGOMETASTATIC PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OLIGOMETASTATIC PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for OLIGOMETASTATIC PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to halt spreading prostate cancer
Disease control OngoingThis phase II trial tests whether adding the hormone-blocking drug relugolix to standard radiation therapy can slow cancer growth in men with prostate cancer that has spread to a few other spots in the body (oligometastatic). About 194 participants will receive either radiation a…
Matched conditions: OLIGOMETASTATIC PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New trial aims to cut side effects of radiation for recurrent prostate cancer
Disease control OngoingThis phase II trial tests two types of radiation therapy (proton beam or IMRT) given in fewer, larger doses for men whose prostate cancer has returned or spread to a few spots after initial treatment. The main goal is to see if this shorter course causes fewer serious side effect…
Matched conditions: OLIGOMETASTATIC PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo attack on returning prostate cancer shows promise in early trial
Disease control OngoingThis phase 2 trial tests whether giving a radioactive drug (177Lu-PSMA) before precise radiation (SBRT) can better control prostate cancer that has come back in 1 to 5 spots. About 93 men with recurrent prostate cancer will receive either SBRT alone or the drug first, then SBRT. …
Matched conditions: OLIGOMETASTATIC PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control OngoingThis study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink …
Matched conditions: OLIGOMETASTATIC PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC